Physician profile
Bethany Fishbein
NPI 1770513525
$1,645.88
in general payments reported to CMS, 2019-2025
19 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $586 · 2021: $161 · 2022: $26.69 · 2023: $323 · 2024: $247 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.68 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $385.28 | 2019-2024 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $323.43 | 2019-2025 | |
| Alcon Vision LLC | $263.50 | 2019-2025 | Dailies Total1, Precision 1, Dailies |
| Astellas Pharma US INC | $141.19 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $122.31 | 2019-2021 | |
| Dompe US, INC. | $59.99 | 2023 | Oxervate |
| Allergan, INC. | $58.32 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.44 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $43.75 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $29.13 | 2021 | |
| Eyevance Pharmaceuticals LLC | $26.80 | 2021-2022 | |
| Visioneering Technologies, INC. | $26.20 | 2020 | |
| Sun Pharmaceutical Industries INC. | $22.61 | 2025 | |
| Bausch & Lomb Americas INC. | $18.15 | 2025 | Xiidra, Miebo |
| Harrow Eye, LLC | $17.66 | 2024 | Vevye |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $13.74 | 2024 | |
| Glaxosmithkline, LLC. | $13.57 | 2021 | |
| Maculogix, INC. | $12.93 | 2020 | |
| Oyster Point Pharma, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Fishbein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.